Reviewing Addex Therapeutics (NASDAQ:ADXN) & Clene (NASDAQ:CLNN)Defense World · Oct 19, 2026
Addex (NASDAQ: ADXN) spin-out Neurosterix clears Phase 1, plans next stageDefense World · Oct 10, 2026
Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for SchizophreniaGlobeNewsWire · Oct 8, 2026
Addex Therapeutics Announces Executive Management ChangesGlobeNewsWire · Oct 2, 2026
What Addex Therapeutics (ADXN) Said on Its Q2 Earnings CallDefense World · Sep 29, 2026
Addex Therapeutics Ltd (ADXN) Q2 2026 Earnings Call TranscriptSeeking Alpha · Sep 28, 2026Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 28, 2026 | – | -$1.49 | |
| Jun 25, 2026 | – | -$1.53 | |
| Apr 30, 2026 | -$1.42 | -$1.94 | Miss |
| Dec 4, 2025 | – | -$1.50 | |
| Nov 10, 2025 | -$1.42 | -$2.91 | Miss |
| Jun 20, 2025 | -$4.26 | -$1.33 | Beat |